We have a team of clinicians and analysts who monitor the pipeline continuously. By the time of its launch, each new product has typically been under our surveillance for three to four years. The surveillance involves a thorough review of available clinical research. We also seek input from external thought leaders, including the Centers for Medicare & Medicaid Services, to help ensure we have a comprehensive perspective.
This in-depth analysis is used to help model impact by client segment. Proactive client briefings and alerts about upcoming specialty drug approvals and launches help to keep our clients informed as new information becomes available. Ongoing collaboration with our clients enhances transparency and helps us formulate strategic plan design options and better solutions.